6-benzylthioinosine

a subversive substrate of T gondii adenosine kinase; structure in first source

Networked: 5 relevant articles (0 outcomes, 0 trials/studies)

1.	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 11/27/2014 - "We previously demonstrated that 6-benzylthioinosine (6-BT) could induce the differentiation of a subset of acute myeloid leukemia (AML) cell lines and primary AML cells regardless of their cytogenetics. " 11/01/2016 - "Synergistic cell death in FLT3-ITD positive acute myeloid leukemia by combined treatment with metformin and 6-benzylthioinosine."
2.	Myeloid Leukemia (Leukemia, Myelocytic) 11/15/2009 - "This paper described the development and validation of a liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for the quantitative determination of 6-benzylthioinosine (6BT), a novel myeloid leukemia differentiation-inducing agent, in mouse and human plasma. " 06/01/2008 - "Identification of 6-benzylthioinosine as a myeloid leukemia differentiation-inducing compound."
3.	Toxoplasmosis 12/19/2005 - "These findings further advance the rationale for developing 6-benzylthioinosine analogues as selective therapeutic agents for the treatment of toxoplasmosis." 12/19/2005 - "Inhibitors of nucleoside transport in mammalian cells can selectively protect the host from the toxicity of toxic purine nucleosides that may be used in future combination therapy against toxoplasmosis or from metabolites of the 6-benzylthioinosine analogues that may be released by the destruction of infected cells. "

1.	Therapeutics